TG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High – Time to Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX) hit a new 52-week high during trading on Tuesday. The company traded as high as $65.35 and last traded at $65.8960, with a volume of 259,927 shares trading hands. The stock had previously closed at $63.38.

TG Therapeutics News Summary

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above analyst expectations of about $245.5 million. The company also reported EPS of $0.35; that was below the $0.37 consensus cited in some market data, though above the $0.28 Zacks estimate. TG Therapeutics reports third-quarter results and raises guidance
• Positive Sentiment: TG Therapeutics raised its 2026 revenue guidance to $1 billion, above the roughly $961 million analyst consensus. CEO Michael Weiss also said global revenue could exceed $1 billion, reinforcing expectations for continued BRIUMVI sales growth. TG Therapeutics targets $1 billion in 2026 global revenue
• Positive Sentiment: The company plans simplified intravenous dosing in mid-2027 and a subcutaneous launch in 2028. These longer-term formulation changes could make treatment more convenient, though their commercial impact is still ahead. TG Therapeutics dosing and launch plans
• Negative Sentiment: EPS of $0.35 fell short of the $0.37 consensus estimate cited in the supplied market data, tempering the otherwise strong revenue report. TG Therapeutics third-quarter earnings report

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Zacks Research upgraded shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. B. Riley Financial lifted their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Weiss Ratings raised shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a research report on Tuesday, September 1st. Finally, JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $63.00.

TG Therapeutics Price Performance

The company has a 50-day moving average of $55.99 and a 200 day moving average of $44.66. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The firm has a market cap of $9.98 billion, a P/E ratio of 23.82, a P/E/G ratio of 2.60 and a beta of 1.89.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.02). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company had revenue of $259.94 million during the quarter, compared to the consensus estimate of $245.47 million. During the same quarter last year, the company earned $2.43 earnings per share. The business’s revenue was up 60.8% on a year-over-year basis. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.92 EPS for the current year.

Insider Buying and Selling

In other news, Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the sale, the director owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 8.87% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of TG Therapeutics during the second quarter worth $1,211,429,000. Bank of America Corp DE bought a new position in shares of TG Therapeutics in the second quarter valued at about $71,960,000. Bank of New York Mellon Corp acquired a new position in TG Therapeutics during the 2nd quarter worth about $49,472,000. Dimensional Fund Advisors LP lifted its position in TG Therapeutics by 129.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock worth $36,029,000 after buying an additional 612,068 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in TG Therapeutics by 697.6% during the 2nd quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company’s stock worth $26,276,000 after buying an additional 418,300 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.